Inovio Pharmaceuticals (INO -11.6%) announces encouraging data from a just-published pilot study evaluating immunotherapy INO-3106 in patients with recurrent respiratory papillomatosis, a rare disorder characterized by the development wart-like growths (papillomas) in the respiratory tract.
The results showed that INO-3106 generated an
immune response and engagement and expansion of an HPV 6-specific
cellular response, including cytotoxic T cells. Two participants who
previously required ~two surgeries each year to manage their disease
were able to delay the need for surgery to a “robust degree.” One was
surgery-free for 584 days while the other has remained surgery-free for
over 915 days.
Shares are down 12% on continued profit-taking from its coronavirus outbreak-stoked runup.
https://seekingalpha.com/news/3537363-inovios-inominus-3106-shows-encouraging-action-in-pilot-study
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.